Who are Lunesta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Noroxin, Flunipam, Lunesta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eszopiclone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lunesta — Competitive Intelligence Brief

Lunesta (ESZOPICLONE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: eszopiclone. Area: Neuroscience.

marketed eszopiclone Gamma-aminobutyric acid receptor subunit alpha-1 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Lunesta (ESZOPICLONE) — Waylis. Lunesta works by enhancing the activity of a neurotransmitter called GABA, which helps calm the brain and promote sleep.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lunesta TARGET	ESZOPICLONE	Waylis	marketed	eszopiclone	Gamma-aminobutyric acid receptor subunit alpha-1	2004-01-01
Noroxin	NORFLOXACIN		marketed	Quinolone Antimicrobial	Gamma-aminobutyric acid receptor subunit alpha-1	1986-01-01
Flunipam	FLUNITRAZEPAM		marketed	flunitrazepam	Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-3
Lunesta	Lunesta	Walter Reed Army Medical Center	marketed		Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (eszopiclone class)

Waylis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lunesta — Competitive Intelligence Brief. https://druglandscape.com/ci/eszopiclone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab